VolitionRx (VNRX) said Thursday it has extended its Nu.Q Vet Cancer Test supply deal with Fujifilm Vet Systems in Japan for a new five-year initial term to include the chemiluminescent immunoassay version of the test through an automated analyzer platform.
The agreement previously allowed Fujifilm to provide the test to Japanese veterinarians in a manual format, VolitionRx said.
Fujifilm will work with VolitionRx for the final validation and verification of the automated platform for canine cancer screening for a launch in the summer, according to VolitionRx.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。